Goldman Sachs raised the firm’s price target on Eli Lilly (LLY) to $1,145 from $951 and keeps a Buy rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly price target lowered to $1,268 from $1,286 at BofA
- Eli Lilly & Co: Strategic Initiatives and Promising Market Opportunities Drive Buy Rating
- Eli Lilly’s Mounjaro recommended for extended use by EMA
- Eli Lilly’s New Study on LY3549492: A Potential Breakthrough in Obesity Treatment
- Eli Lilly’s New Study on LY4213663: A Potential Game-Changer for Rheumatoid Arthritis?